LATEST PUBLICATIONS

Aug 2022

Parra ALC, Freitas CDT, Souza PFN, von Aderkas P, Borchers CH, Beattie GA, Silva FDA, Thornburg RW

PLANT SCIENCE

Aug 2022

Richard VR, Gaither C, Popp R, Chaplygina D, Brzhozovskiy A, Kononikhin A, Mohammed Y, Zahedi RP, Nikolaev EN, Borchers CH

MOLECULAR & CELLULAR PROTEOMICS

Jul 2022

Smith-Byrne K, Cerani A, Guida F, Zhou S, Agudo A, Aleksandrova K, Barricarte A, Rodríguez-Barranco M, Borchers CH, Gram IT, Han J, Amos CI, Hung RJ, Grankvist K, Nøst TH, Imaz L, Chirlaque-López MD, Johansson M, Kaaks R, Kühn T, Martin RM, McKay JD, Pala V, Robbins HA, Sandanger TM, Schibli D, Schulze MB, Travis RC, Vineis P, Weiderpass E, Brennan P, Johansson M, Richards JB

CANCER EPIDEMIOL BIOMARKERS PREV.

LATEST NEWS

A Collaboration for Progress

MRM Proteomics, Inc. (MRMP) and Agilent Technologies Inc. are excited to announce their new co-marketing agreement aimed to further advance the capabilities of quantitative proteomic applications and thereby help the scientific community make impactful, novel scientific discoveries. This new partnership will provide a complete solution for quantitative protein and metabolite analysis. Agilent’s advanced expertise and state-of-the-art mass spectrometry technology, along with MRMP’s leadership and experience in peptide and metabolite quantitation will enable the development of new tools and technologies to advance the field of multi-omics. Read more about this exciting collaboration.

In October, Genome Québec announced the 11 research teams, which represent four universities in Québec, that won major funding in genomics, totalling more than 4 million dollars.  Included in the chosen research teams is MRM Proteomics, who will join forces with McGill University and Bruker to set a new benchmark for the large-scale and reliable measurement of proteins in 1000s of samples with an unprecedented liaison between highest quality and low cost.  This new novel and unique technology will reduce the current cost of such measurements from 1$ per protein to ¢2.  This project will transform health-related research projects where 1000s-10,000s of patient samples can be analyzed and the causes and early markers of either disease or drug response can be identified. This therefore can accelerate global research by preventing and effectively treating disease. While the benefits for society and the health system will be enormous, the global biomarkers market size will reach USD B130 in 2028, with 30-40% of biomarkers being proteins, therefore representing a vast business opportunity with millions of $ in potential revenues.

 

The highly influential journal “Chemical Reviews” recently published a review where our CSO and Co-founder Christoph Borchers and McGill scientist Evgeniy Petrotchenko discuss the potential of structural proteomics for treating neurodegenerative diseases. “This field combines protein chemistry and mass spectrometry, an advanced analytical technique for identifying the chemical composition of substances based on precise mass. The ultimate goal is to resolve the detailed structure of proteins and therefore understand pathological processes, like Alzheimer’s, on the molecular level and predict drug candidates against diverse diseases faster and more efficiently.” Technology networks full news article link.